The study involved two groups: high and low FTRS (FN1+ TCs Risk Score) groups, aimed at investigating the influence of FN1 high-expressing TCs on ovarian cancer patients, utilizing the 10 prognostic mRNAs identified from the TCGA cohort (Figures 11F–H). This evidence concerns the gene FN1 and ovarian carcinoma.